Satsuma

Satsuma Pharmaceuticals, Inc. was founded in South San Francisco, California, in 2016 as a clinical-stage biopharmaceutical company dedicated to developing acute treatments for migraine.STS101 is Satsuma Pharmaceuticals' leading drug candidate for the treatment of migraine. STS101 is a simple-to-use, self-administered, non-injectable dihydroergotamine (DHE) product that utilizes proprietary intranasal delivery, dry-powder formulation, and engineered drug particle delivery technology, positioning it as a potential best-in-class therapy for migraine. DHE offers several therapeutic advantages over other migraine therapies, including triptans, such as rapid absorption and high drug availability, with pharmacokinetic properties similar to injections, providing consistent and robust clinical efficacy. STS101 has undergone extensive preclinical optimization and recently completed a Phase I clinical trial.